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Abstract
4-Amino-2H-benzo[h]chromen-2-one (ABO) and 4-amino-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one (ATBO) analogs were found to be significant in vitro anticancer agents in
our previous research. Our continuing study has now discovered a new simplified (monocyclic
rather than tricyclic) class of cytotoxic agents, 4-amino-2H-pyran-2-one (APO) analogs. By
incorporating various substituents on the pyranone ring, we have established preliminary
structure-activity relationships (SAR). Analogs 19, 20, 23, and 26–30 displayed significant tumor
cell growth inhibitory activity in vitro. The most active compound 27 exhibited ED50 values of
0.059–0.090 μM.
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In 2004, our group first isolated and synthesized neo-tanshinlactone (1).1 Compound 1 was
10-fold more potent and 20-fold more selective as compared with tamoxifen citrate against
the ER+ human breast cancer cell lines MCF-7 and ZR-75-1. Further structural optimization
led to its 4-ethyl analog 2, which displayed significant and selective anti-breast cancer
activity both in vitro and in vivo.2.3 Moreover, 2 was selective for a subset of breast cancer-
derived cell lines and significantly less active against normal breast-derived tissue. In order
to explore the effect of individual rings on the anticancer activity, identify new lead
compounds, and discover new chemical entities, we designed and reported five classes of
new anticancer agents, including 2-(furan-2-yl)naphthalen-1-ol (FNO),4 6-phenyl-4H-
furo[3,2-c]pyran-4-one (AFPO),5 tetrahydronaphthalene-1-ol (TNO),6 4-amino-2H-
benzo[h]chromen-2-one (ABO, 3, Figure 1),7 and 4-amino-7,8,9,10-tetrahydro-2H-
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benzo[h]chromen-2-one (ATBO, 4, Figure 1)8 analogs. Interestingly, the neo-
tanshinlactone-inspired synthesis of a breast cancer selective ABO series was reported
independently by others.9
Importantly, ABO and ATBO compounds displayed much higher potency than 1-analogs,
which encouraged us to further investigate these scaffolds. Structure-activity relationship
(SAR) studies on 3 and 4 indicated that (1) a secondary amine (R2 or R3 = H) is preferred
over tertiary amine (R2 and R3 ≠ H), (2) bulky groups are favored at the R2/R3 position, (3)
a 3′-bromophenyl group can cause a dramatic loss of potency, and (4) a non-aromatic ring-A
can increase potency and cancer cell line selectivity for certain analogs. Our studies also
indicated that the lactone ring-C is critical to the cytotoxic activity.3,7,8 Therefore, we
designed a structurally simplified monocyclic scaffold (5, Figure 1) and incorporated
various substituents at the R and R′ positions to explore the contributions of ring-A and -B,
develop new chemical entities and new leads, and establish the SAR. Herein, we report the
design, synthesis, and biological activity of 4-amino-2H-pyran-2-one (APO) analogs.
As a first step in the current work, we designed two model compounds 12 and 13 by
eliminating the fused ring-A/B system and incorporating pendant phenyl and styryl groups,
respectively, on the remaining pyranone C-ring. 6-Substituted 4-hydroxy-2H-pyran-2-one
10 was synthesized according to the method reported by Bach et al.10 The appropriate
aldehyde (6) and an acetoacetate equivalent (7) underwent a vinylogous Mukaiyama aldol
addition to give 8, which was oxidized to 9 using the Dess–Martin method. A thermal
cyclization of 9 yielded 4-hydroxy-2H-pyranone 10. Chlorination followed by amination of
10 provided model compounds 12 and 13.7
Analogs 12 and 13 were tested for in vitro cytotoxic activity against a panel of human tumor
cell lines according to previously published methods (Table 1).3 Cell lines included A549
(non small cell lung cancer), DU145 (prostate cancer cell line), KB (nasopharyngeal
carcinoma), and KB-VIN (vincristine-resistant MDR KB subline), SK-BR-3 (estrogen
receptor negative, HER2 over-expressing breast cancer). Importantly, 13 showed significant
inhibition of all human cancer cell lines tested with ED50 values from 1.23–2.02 μM, while
12 displayed moderate activity.
Encouraged by these promising results, analogs 14–30 were designed to establish SAR
correlations as well as to optimize structure and identify more active derivatives with the
desired biological properties. Firstly, we installed various groups at the pyranone 6-position
(R group) to explore the effect of group size, ring size, and aromaticity. Secondly, different
substituents at the pyranone 4-position (R′ group) were investigated while retaining the best
R group. As shown in Scheme 1, new analogs 14–30 were obtained through the five-step
procedure similarly to 12 and 13, and then evaluated against five human tumor cell lines
from different tissues.
Compounds 14 and 15 with methyl and isopropyl R groups were not active, and 16–18 with
pentyl, cyclopentyl, and cyclohexyl groups showed moderate activity. These results
suggested that long alkyl chains and cyclic alkyl groups were favored at the pyranone 6-
position. Compounds 19–23, which contain different aromatic R groups, including phenyl,
styryl, benzyl, furanyl, and naphthyl, displayed significant activity. Especially, 19 and 20
with phenyl and styryl groups, respectively, were the most potent analogs with ED50 values
of 0.079–0.163 μM, and were equally or slightly more potent than ABO analog 3. The
results indicated that an aromatic ring at the pyranone 6-position may be critical to the
cytotoxic activity.
Based on structural simplicity and chemical availability as well as the above results, we
designed analogs 24–30, which have various substituents at the pyranone 4-position and a
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phenyl group fixed at the 6-position. Among them, 26–30 with substituted aniline groups
displayed significant activity against all tested tumor cell lines compared with analogs
containing cycloalkyl groups, including cyclohexylamine (12), cyclopropylamine (24), and
piperidine (25). The latter two compounds totally lost cytotoxic activity. These data indicate
that an aromatic amino R′ group is favored at the 4-position. In addition, the position and
type of substituent on the aniline ring played an important role in the cytotoxic activity. The
rank order of potency for all aromatic analogs against KB was 27 (4′-Me) > 19 (4′-OMe) >
26 (H) > 28 (4′-Br) ~ 29 (2′-OMe) ~ 30 (3′-OMe). 4-Methylaniline-substituted 27 was the
most potent analog with ED50 values of 0.059–0.090 μM. It was about two-fold more potent
than ABO analog 3.
Overall, 19 and 27 showed greater in vitro antitumor activity than other analogs, suggesting
that the combination of a phenyl group at the 6-position and a 4′-methyl- or 4′-methoxy-
aniline at the 4-position is favored for the APO analogs.
In summary, we designed and developed a new class (APO) of in vitro anticancer agents,
through structural simplification and optimization. Lead compounds displayed potent
antitumor activity with ED50 values in the low micromolar range. SAR studies indicated
that: (1) an aromatic ring such as phenyl and styryl at the pyranone 6-position is critical to
the antitumor activity, (2) a secondary amine at the 4-position is preferred over a tertiary
amine, (3) aromatic amine groups at the 4-position are crucial, and (4) substituents on the
aromatic amine group can increase potency. Compounds 19 and 27 were the most potent
analogs (ED50 values of 0.059–0.163 μM) among all derivatives, and thus, are new lead
compounds that are promising for further development of potential clinical trials candidates.
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1.6 Hz, 3-H), 4.94 (d, 1H, J = 7.2 Hz, NH), 3.29 (m, 1H, NCH), 2.05 (m, 2H, NCHCH2), 1.78 (m,
2H, NCHCH2), 1.26 (m, 6H, cyclohexyl-H). MS m/z 270 (M++1). (E)-4-(Cyclohexylamino)-6-
styryl-2H-pyran-2-one (13) 1H NMR (400 MHz, DMSO-d6): δ 7.47 (m, 3H, Ar & olefin-H),
7.32 (m, 3H, Ar-H), 6.53 (d, 1H, J = 13.6 Hz, olefin-H), 5.71 (s, 1H, 3-H), 5.08 (d, 1H, J = 1.6
Hz,), 4.73 (d, 1H, J = 7.2 Hz, NH), 3.27 (m, 1H, NCH), 2.05 (m, 2H, NCHCH2), 1.78 (m, 2H,
NCHCH2), 1.26 (m, 6H, cyclohexyl-H). MS m/z 296 (M++1). 4-[(4-Methoxyphenyl)amino]-6-
methyl-2H-pyran-2-one (14) 1H NMR (400 MHz, CD3OD): δ 7.14 (d, 2H, J = 8.8 Hz, Ar-H),
6.97 (d, 2H, J = 8.8 Hz, Ar-H), 5.97 (d, 1H, J = 2.0 Hz, 5-H), 5.14 (d, 1H, J = 1.6 Hz, 3-H), 3.82
(s, 1H, 4′-OCH3), 2.20 (d, 3H, J = 0.8 Hz, 6-CH3). MS m/z 230 (M+-1). 6-Isopropyl-4-[(4-
methoxyphenyl)amino]-2H-pyran-2-one (15) 1H NMR (400 MHz, CD3OD): δ 7.15 (d, 2H, J =
8.8 Hz, Ar-H), 6.97 (d, 2H, J = 8.8 Hz, Ar-H), 5.97 (d, 1H, J = 2.0 Hz, 5-H), 5.15 (d, 1H, J = 1.6
Hz, 3-H), 3.81 (d, 3H, J = 1.2 Hz, 4′-OCH3), 2.72 (h, 1H, J = 6.8 Hz, isopropyl-H), 1.24 (d, 6H, J
= 6.8 Hz, isopropyl-H). MS m/z 258 (M+-1). 4-[(4-Methoxyphenyl)amino]-6-pentyl-2H-
pyran-2-one (16) 1H NMR (400 MHz, CD3OD): δ 7.15 (d, 2H, J = 9.2 Hz, Ar-H), 6.97 (d, 2H, J
= 8.8 Hz, Ar-H), 5.97 (d, 1H, J = 2.4 Hz, 5-H), 5.15 (d, 1H, J = 2.4 Hz, 3-H), 3.81 (s, 3H, 4′-
OCH3), 2.46 (t, 2H, J = 7.6 Hz, pentyl-H), 1.66 (p, 2H, J = 7.6 Hz, pentyl-H), 1.34–1.38 (m, 4H,
pentyl-H), 0.93 (t, 3H, J = 7.2 Hz, pentyl-H). MS m/z 286 (M+-1). 6-Cyclopentyl-4-[(4-
methoxyphenyl)amino]-2H-pyran-2-one (17) 1H NMR (400 MHz, CD3OD): δ 7.14 (d, 2H, J =
8.8 Hz, Ar-H), 6.97 (d, 2H, J = 8.8 Hz, Ar-H), 5.99 (d, 1H, J = 2.4 Hz, 5-H), 5.14 (d, 1H, J = 2.0
Hz, 3-H), 3.81 (s, 3H, 4′-OCH3), 2.40 (m, 1H, cyclopentyl-H), 2.89 (p, 1H, J = 8.0 Hz,
cyclopentyl-H), 1.96–2.01 (m, 2H, cyclopentyl-H), 1.66–1.82 (m, 6H, cyclopentyl-H). MS m/z 284
(M+-1). 6-Cyclohexyl-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (18) 1H NMR (400 MHz,
CD3OD): δ 7.14 (d, 2H, J = 8.8 Hz, Ar-H), 6.97 (d, 2H, J = 8.8 Hz, Ar-H), 5.95 (s, 1H, 5-H), 5.15
(s, 1H, 3-H), 3.81 (s, 1H, 4′-OCH3), 2.40 (m, 1H, cyclohexyl-H), 1.72–1.94 (m, 5H, cyclohexyl-
H), 1.25–1.47 (m, 5H, cyclohexyl-H). MS m/z 298 (M+-1). 4-[(4-Methoxyphenyl)amino]-6-
phenyl-2H-pyran-2-one (19) 1H NMR (400 MHz, CDCl3): δ 7.82–7.85 (m, 2H, Ar-H), 7.48–
7.51 (m, 3H, Ar-H), 7.20 (d, 2H, J = 8.8 Hz, Ar-H), 7.00 (d, 2H, J = 8.8 Hz, Ar-H), 6.66 (d, 1H, J
= 2.0 Hz,5-H), 5.29 (d, 1H, J = 2.0 Hz, 3-H), 3.83 (s, 3H, 4′-OCH3). MS m/z 292 (M+-1). (E)-4-
[(4-Methoxyphenyl)amino]-6-styryl-2H-pyran-2-one (20) 1H NMR (400 MHz, CD3OD): δ 7.60
(d, 2H, J = 7.2 Hz, Ar-H), 7.33–7.44 (m, 4H, Ar & olefin-H), 7.17–7.20 (m, 2H, Ar-H), 6.98–7.00
(m, 2H, Ar-H), 6.85 (d, 1H, J = 16.0 Hz, olefin-H), 6.20 (d, 1H, J = 2.0 Hz, 5-H), 5.25 (d, 1H, J =
1.6 Hz, 3-H), 3.82 (s, 1H, 4′-OCH3). MS m/z 318 (M+-1). 6-Benzyl-4-[(4-
methoxyphenyl)amino]-2H-pyran-2-one (21) 1H NMR (400 MHz, CD3OD): δ 7.30–7.36 (m,
5H, Ar-H), 7.11 (d, 2H, J = 8.8 Hz, Ar-H), 6.95 (d, 2H, J = 9.2 Hz, Ar-H), 5.89 (s, 1H, 5-H), 5.14
(d, 1H, J = 1.6 Hz, 3-H), 3.80 (s, 3H, 4′-OCH3), 3.79 (s, 2H, 6-CH2). MS m/z 306 (M+-1). 6-
(Furan-2-yl)-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (22) 1H NMR (400 MHz, CDCl3):
δ 7.68 (s, 1H, Ar-H), 7.18 (d, 2H, J = 8.8 Hz, Ar-H), 6.98–7.00 (m, 3H, Ar-H), 6.61–6.63 (m, 1H,
Ar-H), 6.49 (d, 1H, J = 1.6 Hz, 5-H), 5.22 (d, 1H, J = 2.0 Hz, 3-H), 3.82 (s, 3H, 4′-OCH3). MS m/z
282 (M+-1). 4-[(4-Methoxyphenyl)amino]-6-(naphthalen-2-yl)-2H-pyran-2-one (23) 1H NMR
(400 MHz, CD3OD): δ 8.42 (s, 1H, Ar-H), 7.86–7.99 (m, 4H, Ar-H), 7.57–5.59 (m, 2H, Ar-H),
7.23 (d, 2H, J = 8.8 Hz, Ar-H), 7.02 (d, 2H, J = 9.2 Hz, Ar-H), 6.81 (d, 1H, J = 2.0 Hz,5-H), 5.33
(d, 1H, J = 2.0 Hz, 3-H), 3.84 (s, 3H, 4′-OCH3). MS m/z 342 (M+-1). 4-(Cyclopropylamino)-6-
phenyl-2H-pyran-2-one (24) 1H NMR (400 MHz, CD3OD): δ 7.80 (m, 2H, Ar-H), 7.46 (m, 3H,
Ar-H), 6.46 (s, 1H, 5-H), 5.41 (s, 1H, 3-H), 2.52 (s, 1H, 1′-H), 0.85 (d, 2H, J = 6.4 Hz,2′ & 3′-H),
0.58 (m, 2H, 2′ & 3′-H). MS m/z 226 (M+-1). 6-Phenyl-4-(piperidin-1-yl)-2H-pyran-2-one
(25) 1H NMR (400 MHz, CD3OD): δ 7.89–7.92 (m, 2H, Ar-H), 7.47–7.49 (m, 3H, Ar-H), 6.92 (d,
1H, J = 1.6 Hz,5-H), 5.28 (d, 1H, J = 2.0 Hz, 3-H), 3.57 (t, 4H, J = 4.8 Hz, 2′ & 6′-H), 1.68–1.75
(m, 6H, 3′, 4′, & 5′-H). MS m/z (M+-1). 6-Phenyl-4-(phenylamino)-2H-pyran-2-one (26) 1H
NMR (400 MHz, DMSO-d6): δ 9.42 (s, 1H, NH), 7.76–7.78 (m, 2H, Ar-H), 7.53–7.56 (m, 3H, Ar-
H), 7.44 (t, 2H, J = 7.6 Hz, Ar-H), 7.28 (d, 2H, J = 8.4 Hz, Ar-H), 7.21 (t, 1H, J = 7.2 Hz, Ar-H),
6.70 (d, 1H, J = 1.6 Hz,5-H), 5.34 (t, 1H, J = 1.2 Hz, 3-H). MS m/z 262 (M+-1). 6-Phenyl-4-(p-
tolylamino)-2H-pyran-2-one (27) 1H NMR (400 MHz, CD3OD): δ 7.83–7.86 (m, 2H, Ar-H),
7.50–7.52 (m, 3H, Ar-H), 7.26 (d, 2H, J = 8.4 Hz, Ar-H), 7.17 (d, 2H, J = 8.4 Hz, Ar-H), 6.69 (d,
1H, J = 2.0 Hz,5-H), 5.41 (d, 1H, J = 2.0 Hz, 3-H), 2.37 (s, 3H, CH3). MS m/z 276 (M+-1). 4-[(4-
Bromophenyl)amino]-6-phenyl-2H-pyran-2-one (28) 1H NMR (400 MHz, CD3OD): δ 7.84–
7.87 (m, 2H, Ar-H), 7.59 (d, 1H, J = 8.4 Hz, Ar-H), 7.50–7.52 (m, 3H, Ar-H), 7.23 (d, 1H, J = 8.8
Hz, Ar-H), 6.70 (d, 1H, J = 2.0 Hz,5-H), 5.50 (d, 1H, J = 2.0 Hz, 3-H). MS m/z 340 (M+-1). 4-[(2-
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Methoxyphenyl)amino]-6-phenyl-2H-pyran-2-one (29) 1H NMR (400 MHz, CD3OD): δ 7.83–
7.86 (m, 2H, Ar-H), 7.50–7.52 (m, 3H, Ar-H), 7.34 (t, 1H, J = 8.0 Hz, Ar-H), 6.81–6.89 (m, 3H,
Ar-H), 6.71 (d, 1H, J = 2.0 Hz,5-H), 5.53 (d, 1H, J = 2.0 Hz, 3-H), 3.82 (s, 3H, 4′-OCH3). MS m/z
292 (M+-1). 4-[(3-Methoxyphenyl)amino]-6-phenyl-2H-pyran-2-one (30) 1H NMR (400 MHz,
CD3OD): δ 7.83–7.86 (m, 2H, Ar-H), 7.50–7.52 (m, 3H, Ar-H), 7.34 (t, 1H, J = 8.0 Hz, Ar-H),
6.81–6.89 (m, 3H, Ar-H), 6.71 (d, 1H, J = 2.0 Hz,5-H), 5.53 (d, 1H, J = 2.0 Hz, 3-H), 3.82 (s, 3H,
4′-OCH3). MS m/z 292 (M+-1).
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Structures of neo-tanshinlactone (1), 4-ethyl neo-tanshinlactone (2), previously reported
ABO (3) and ATBO (4) scaffolds, and newly designed APO scaffold (5)
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Reagents and conditions: (a) TiCl4, CH2Cl2, -78 °C; (b) Dess-Martin reagent, rt; (c) toluene,
reflux; (d) POCl3, Et3N, reflux, 1h; (e) aliphatic amines, EtOH, reflux, 2h; (f) aromatic
amines, ethylene glycol, 160 °C, 1h.
Dong et al. Page 7


















































































































































































































































































































































Bioorg Med Chem Lett. Author manuscript; available in PMC 2012 April 15.
